High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer

Yu Mei Liao, Ya Hui Wang, Jung Tung Hung, Yu Ju Lin, Yen Lin Huang, Guo Shiou Liao, Ya Ling Hsu, Jen Chien Wu, Alice L. Yu*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

11 Scopus citations


Background: Existence of breast cancer stem cells (BCSCs) is implicated in disease relapse, metastasis, and resistance of treatment. β1,3-Galactosyltransferase 5 (B3GALT5) has been shown to be a pro-survival marker for BCSCs. However, little is known about the prognostic significance of B3GALT5 in breast cancer. Methods: Paired tissues (tumor part and adjacent non-tumor part) from a cohort of 202 women with breast cancer were used to determine the expression levels of B3GALT5 mRNA by qRT-PCR. Kaplan–Meier and multivariable Cox proportional hazard models were used to assess survival differences in terms of relapse-free survival (RFS) and overall survival (OS). Both breast cancer cells and cancer stem cells (BCSCs) were used to see the in vitro effects of knockdown or overexpression of B3GALT5 on cell migration, invasion, and epithelial-to-mesenchymal transition (EMT). A patient-derived xenograft (PDX) model was used to see the in vivo effects of knockdown of B3GALT5 in BCSCs on tumor growth and metastasis. Results: Higher expression of B3GALT5 in 202 breast cancer tissues, especially in adjacent non-tumor tissue, correlated with poor clinical outcomes including shorter OS and RFS in all patients, especially those with early stage breast cancer. In vitro studies showed B3GALT5 could enhance cell migration, invasion, mammosphere formation, and EMT. Of note, B3GALT5 upregulated the expression of β-catenin and EMT activator zinc finger E-box binding homeobox 1 (ZEB1) pathway in BCSCs. In vivo studies showed B3GALT5 expression in BCSCs is critical for not only tumor growth but also lymph node and lung metastasis in PDX mice. Conclusion: Our results demonstrated the value of B3GALT5 as a prognostic marker of breast cancer, especially among the early stage patients, and its crucial roles in regulating EMT, cell migration, and stemness thereby promoting breast cancer progression.

Original languageEnglish
Article number5
JournalBreast Cancer Research
Issue number1
StatePublished - 12 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).


  • B3GALT5
  • Breast cancer
  • Clinical outcome
  • EMT
  • Metastasis


Dive into the research topics of 'High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer'. Together they form a unique fingerprint.

Cite this